Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on May 12, 2022 12:26am
222 Views
Post# 34676619

Dilution to make your head spin.

Dilution to make your head spin.Long shares are about to get raked over the coals beyond the 2 to 1 and 100 to 1 reverse splits. Offering Price lowered and Shares/Warrants increased. Additional 500,000 Shares + 500,000 Warrants for public offering and underwriters. 8M Capital Raise to 8.4M Capital Raise. Total Shares + Warrants up for grabs - 4,363,984 Current Outstanding Shares - 1,674,868 Current Warrants - 527,770 Outstanding Shares after public offering - 3,856,860 Warrants after public offering - 2,709,762 Fully Diluted Shares - 6,566,622 Form F1/A Amendment #4 - Filed April 25 2022 1,684,210 Units, each Unit Consisting of One Common Share and one Warrant to Purchase one Common Share 1,684,210 Pre-funded Units, each Pre-funded Unit Consisting of one Pre-Funded Warrant to Purchase one Common Share and one Warrant to Purchase one Common Share We will sell these Units at a public offering price of US$4.75 per Unit. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of 110% of the price of the Units in this offering https://www.sec.gov/Archives/edgar/data/0001642178/000106299322010694/formf1a.htm Form F1/A Amendment #5 - Filed May 9 2022 In December 2021, we became a remote-first company. Accordingly, we do not currently maintain a headquarters. 1,931,922 Units, each Unit Consisting of One Common Share and one Warrant to Purchase one Common Share 1,931,922 Pre-funded Units, each Pre-funded Unit Consisting of one Pre-Funded Warrant to Purchase one Common Share and one Warrant to Purchase one Common Share ...based on an assumed offering price per Unit of US$4.348, the last reported price of our Common Shares as reported on the OTC Market Group Inc.'s Venture Market (the "OTCQB") on May 5, 2022. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of 110% of the price of the Units in this offering We have granted the underwriters a 45-day option (commencing from the date of this Prospectus) to purchase up to an additional 289,788 Common Shares and/or up to an additional 289,788 Warrants at the public offering price per Common Share and per Warrant respectively https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011852/formf1a.htm FWP (Prospectus) - Filed May 10 2022 https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011950/formfwp.htm A free writing prospectus (FWP) is a written communication regarding securities being publicly offered disseminated by the issuer during the waiting period of an initial public offering (IPO) that discloses information that would not be included in the registration statement. https://www.law.cornell.edu wex Comment: Longs holding pre-split shares will need a Market Cap of $200M USD to break even. Basically dead money here for the foreseeable future. As I see nothing in the pipeline to get to that valuation prior to a standalone clinical trial for Chronic Cough with stat SIG results better than Bellus Health. Meanwhile, the walls around Algernon appear to be on fire but for the fact the company no longer has a corporate office. Pure insanity with Moreau's prior BS decisions and timelines driving the company over every cliff imaginable. Moreau stated his goal was to provide shareholders with "Life-changing" returns on their investment. Uhh ok. In what lifetime - this one or the next? A standalone Chronic Cough Phase 3 clinical trial should already be underway. It's the best shot at success purchased by shareholders back in 2018. Christopher Moreau is unequivocally the absolute worst "CEO" ever. Stay tuned https://algernonpharma.com/ https://cdn-ceo-ca.s3.amazonaws.com/1h7p2tk-little-nicky-head-spin.gif
<< Previous
Bullboard Posts
Next >>